Clinical Trial

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

Study acronym: O3NPIQ
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-03-06; most recent amendment 2025-08-25.
Status change: Not Yet Recruiting → Recruiting 2020-12-02
Trial Details
NCT Number NCT04299893
Lead Sponsor Bernardino Clavo, MD, PhD
Collaborators: Servicio Canario de Salud, Instituto de Salud Carlos III, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Fundación DISA, Spain, Fundación Española del Dolor (FED)
Conditions Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain Syndrome
Enrollment 42 participants
Start Date 2020-11-30
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-02